NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.
Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Good day, and thank you for standing by. Welcome to the NeurAxis’ Fourth Quarter 2024 Financial Results Conference Call. At this time, all ...
NeurAxis, Inc. (NYSE: NRXS) shares began Thursday positive. The company, a medical technology firm commercializing neuromodulation therapies for chronic and debilitating conditions in children and ...
6d
Gross margin in the fourth quarter of 2024 remained steady at 86.4% during the fourth quarters ended December 31, 2024 and 2023. The Company maintained its gross margin by growing its higher margin ...
Brian Carrico, CEO commented, “Our strong performance in 4Q24 capped off a transformational year, as we significantly expanded insurance ...
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic ...
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in ...
The financing will be used to advance Augmenta's AI-powered building design agents and tackle the construction industry's productivity and sustainability challenges TORONTO, March 12, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback